BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 10617689)

  • 1. Nonconserved residues in the second transmembrane-spanning domain of the D(4) dopamine receptor are molecular determinants of D(4)-selective pharmacology.
    Schetz JA; Benjamin PS; Sibley DR
    Mol Pharmacol; 2000 Jan; 57(1):144-52. PubMed ID: 10617689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The binding-site crevice of the D4 dopamine receptor is coupled to three distinct sites of allosteric modulation.
    Schetz JA; Sibley DR
    J Pharmacol Exp Ther; 2001 Feb; 296(2):359-63. PubMed ID: 11160618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural determinants of pharmacological specificity between D(1) and D(2) dopamine receptors.
    Lan H; Durand CJ; Teeter MM; Neve KA
    Mol Pharmacol; 2006 Jan; 69(1):185-94. PubMed ID: 16236817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. S 18126 ([2-[4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)piperazin-1-yl methyl]indan-2-yl]), a potent, selective and competitive antagonist at dopamine D4 receptors: an in vitro and in vivo comparison with L 745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2, 3b]pyridine) and raclopride.
    Millan MJ; Newman-Tancredi A; Brocco M; Gobert A; Lejeune F; Audinot V; Rivet JM; Schreiber R; Dekeyne A; Spedding M; Nicolas JP; Peglion JL
    J Pharmacol Exp Ther; 1998 Oct; 287(1):167-86. PubMed ID: 9765336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and evaluation of fluorine-substituted 1H-pyrrolo[2,3-b]pyridine derivatives for dopamine D4 receptor imaging.
    Oh SJ; Lee KC; Lee SY; Ryu EK; Saji H; Choe YS; Chi DY; Kim SE; Lee J; Kim BT
    Bioorg Med Chem; 2004 Nov; 12(21):5505-13. PubMed ID: 15465327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological profile of L-745,870, a selective antagonist with high affinity for the dopamine D4 receptor.
    Patel S; Freedman S; Chapman KL; Emms F; Fletcher AE; Knowles M; Marwood R; Mcallister G; Myers J; Curtis N; Kulagowski JJ; Leeson PD; Ridgill M; Graham M; Matheson S; Rathbone D; Watt AP; Bristow LJ; Rupniak NM; Baskin E; Lynch JJ; Ragan CI
    J Pharmacol Exp Ther; 1997 Nov; 283(2):636-47. PubMed ID: 9353380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor.
    Grundt P; Carlson EE; Cao J; Bennett CJ; McElveen E; Taylor M; Luedtke RR; Newman AH
    J Med Chem; 2005 Feb; 48(3):839-48. PubMed ID: 15689168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of critical extracellular loop residues involved in alpha 1-adrenergic receptor subtype-selective antagonist binding.
    Zhao MM; Hwa J; Perez DM
    Mol Pharmacol; 1996 Nov; 50(5):1118-26. PubMed ID: 8913343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification and pharmacological characterization of [125I]L-750,667, a novel radioligand for the dopamine D4 receptor.
    Patel S; Patel S; Marwood R; Emms F; Marston D; Leeson PD; Curtis NR; Kulagowski JJ; Freedman SB
    Mol Pharmacol; 1996 Dec; 50(6):1658-64. PubMed ID: 8967990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolism of A dopamine D(4)-selective antagonist in rat, monkey, and humans: formation of A novel mercapturic acid adduct.
    Zhang KE; Kari PH; Davis MR; Doss G; Baillie TA; Vyas KP
    Drug Metab Dispos; 2000 Jun; 28(6):633-42. PubMed ID: 10820134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cysteine residues are involved in structure and function of melanocortin 1 receptor: Substitution of a cysteine residue in transmembrane segment two converts an agonist to antagonist.
    Frändberg PA; Doufexis M; Kapas S; Chhajlani V
    Biochem Biophys Res Commun; 2001 Mar; 281(4):851-7. PubMed ID: 11237737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and pharmacological evaluation of potent and highly selective D3 receptor ligands: inhibition of cocaine-seeking behavior and the role of dopamine D3/D2 receptors.
    Campiani G; Butini S; Trotta F; Fattorusso C; Catalanotti B; Aiello F; Gemma S; Nacci V; Novellino E; Stark JA; Cagnotto A; Fumagalli E; Carnovali F; Cervo L; Mennini T
    J Med Chem; 2003 Aug; 46(18):3822-39. PubMed ID: 12930145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [3H] A-369508 ([2-[4-(2-cyanophenyl)-1-piperazinyl]-N-(3-methylphenyl) acetamide): an agonist radioligand selective for the dopamine D4 receptor.
    Moreland RB; Terranova MA; Chang R; Uchic ME; Matulenko MA; Surber BW; Stewart AO; Brioni JD
    Eur J Pharmacol; 2004 Aug; 497(2):147-54. PubMed ID: 15306199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cluster of aromatic residues in the sixth membrane-spanning segment of the dopamine D2 receptor is accessible in the binding-site crevice.
    Javitch JA; Ballesteros JA; Weinstein H; Chen J
    Biochemistry; 1998 Jan; 37(4):998-1006. PubMed ID: 9454590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Certain 1,4-disubstituted aromatic piperidines and piperazines with extreme selectivity for the dopamine D4 receptor interact with a common receptor microdomain.
    Kortagere S; Gmeiner P; Weinstein H; Schetz JA
    Mol Pharmacol; 2004 Dec; 66(6):1491-9. PubMed ID: 15448188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and structure-affinity relationships of novel N-(1-ethyl-4-methylhexahydro-1,4-diazepin-6-yl)pyridine-3-carboxamides with potent serotonin 5-HT3 and dopamine D2 receptor antagonistic activity.
    Hirokawa Y; Fujiwara I; Suzuki K; Harada H; Yoshikawa T; Yoshida N; Kato S
    J Med Chem; 2003 Feb; 46(5):702-15. PubMed ID: 12593651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a Zn2+-binding site on the dopamine D2 receptor.
    Liu Y; Teeter MM; DuRand CJ; Neve KA
    Biochem Biophys Res Commun; 2006 Jan; 339(3):873-9. PubMed ID: 16332354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Binding sites and transduction process of the cholecystokininB receptor: involvement of highly conserved aromatic residues of the transmembrane domains evidenced by site-directed mutagenesis.
    Jagerschmidt A; Guillaume N; Roques BP; Noble F
    Mol Pharmacol; 1998 May; 53(5):878-85. PubMed ID: 9584214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 2-[4-(3,4-Dimethylphenyl)piperazin-1-ylmethyl]-1H benzoimidazole (A-381393), a selective dopamine D4 receptor antagonist.
    Nakane M; Cowart MD; Hsieh GC; Miller L; Uchic ME; Chang R; Terranova MA; Donnelly-Roberts DL; Namovic MT; Miller TR; Wetter JM; Marsh K; Stewart AO; Brioni JD; Moreland RB
    Neuropharmacology; 2005 Jul; 49(1):112-21. PubMed ID: 15992586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3-((4-(4-Chlorophenyl)piperazin-1-yl)-methyl)-1H-pyrrolo-2,3-b-pyridine: an antagonist with high affinity and selectivity for the human dopamine D4 receptor.
    Kulagowski JJ; Broughton HB; Curtis NR; Mawer IM; Ridgill MP; Baker R; Emms F; Freedman SB; Marwood R; Patel S; Patel S; Ragan CI; Leeson PD
    J Med Chem; 1996 May; 39(10):1941-2. PubMed ID: 8642550
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.